These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18424340)

  • 1. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency.
    Berger M
    Immunol Allergy Clin North Am; 2008 May; 28(2):413-37, x. PubMed ID: 18424340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose and outcomes in primary immunodeficiency disorders.
    Bonagura VR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):7-9. PubMed ID: 25546743
    [No Abstract]   [Full Text] [Related]  

  • 3. Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.
    von Gunten S
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):151-2. PubMed ID: 25546801
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
    Kobayashi RH; Litzman J; Rizvi S; Kreuwel H; Hoeller S; Gupta S
    Immunotherapy; 2022 Mar; 14(4):259-270. PubMed ID: 34986666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7(th) International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):139-40. PubMed ID: 25546796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG replacement therapy, no size fits all.
    Bonilla FA
    Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364
    [No Abstract]   [Full Text] [Related]  

  • 10. 7th International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):162. PubMed ID: 25546805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
    Berger M
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America.
    Condino-Neto A; Costa-Carvalho BT; Grumach AS; King A; Bezrodnik L; Oleastro M; Leiva L; Porras O; Espinosa-Rosales FJ; Franco JL; Sorensen RU
    Allergol Immunopathol (Madr); 2014; 42(3):245-60. PubMed ID: 23333411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the use of immunoglobulin in human disease: A review of evidence.
    Perez EE; Orange JS; Bonilla F; Chinen J; Chinn IK; Dorsey M; El-Gamal Y; Harville TO; Hossny E; Mazer B; Nelson R; Secord E; Jordan SC; Stiehm ER; Vo AA; Ballow M
    J Allergy Clin Immunol; 2017 Mar; 139(3S):S1-S46. PubMed ID: 28041678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New choices for treatment with subcutaneous immunoglobulins.
    Pleguezuelo DE; Sánchez-Ramón S
    Med Clin (Barc); 2017 Jan; 148(2):86-90. PubMed ID: 27919413
    [No Abstract]   [Full Text] [Related]  

  • 15. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
    Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
    J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).
    Gardulf A
    Immunotherapy; 2016 May; 8(5):633-47. PubMed ID: 27020964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous immunoglobulin therapy].
    Mouthon L
    Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.
    Fu LW; Song C; Isaranuwatchai W; Betschel S
    Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Europe immunoglobulin map.
    Šedivá A; Chapel H; Gardulf A;
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):141-3. PubMed ID: 25546797
    [No Abstract]   [Full Text] [Related]  

  • 20. Overview of routes of IgG administration.
    Torgerson TR
    J Clin Immunol; 2013 Jan; 33 Suppl 2():S87-9. PubMed ID: 23229780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.